Tags : golimumab

Biosimilars

Bio-Thera Signs a License Agreement with Pharmapark for BAT2506 (golimumab,

Shots: Bio-Thera will take care of full development, and commercial supply of BAT2506 out of the manufacturing facilities in Guangzhou, China. Additionally, the agreement will utilize Pharmapark’s local presence, sales, and marketing capabilities in Russia and other CIS countries Pharmapark to get exclusive rights to distribute and market the product in Russia and other CIS […]Read More